Position in BCRX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$759,080
+$652,896 QoQ
Shares Held
75,908
+580.5% QoQ
Ownership
0.030%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#135
of 316 holders
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 2%
Shared 23%
None 75%
Common Shares in BCRX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Cerity Partners LLC holds $67,490,391 across 30 Drug Manufacturers - Specialty & Generic names. BCRX ranks #14 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
123,778 | $20,861,543 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
20,210 | $10,950,383 | |
| 3 | ZTS |
Zoetis Inc.
|
90,284 | $6,487,806 | |
| 4 | VTRS |
Viatris Inc
|
280,668 | $4,457,007 | |
| 5 | HLN |
Haleon plc
|
443,467 | $4,137,546 | |
| 6 | TEVA |
Teva Pharmaceutical Industries Ltd
|
106,508 | $3,608,490 | |
| 7 | RDY |
Dr Reddys Laboratories Ltd
|
184,772 | $2,677,345 | |
| 8 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
40,488 | $2,589,207 |
All Filings in BCRX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $759,080 | 75,908 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $106,184 | 11,154 | Shares | Other | 2026-05-15 | |
| 2025-09-30 | $193,711 | 25,522 | Shares | Other | 2025-10-22 | |
| 2025-06-30 | $257,725 | 28,764 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $273,075 | 36,410 | Shares | Sole | 2025-04-30 | |
| 2024-12-31 | $90,179 | 11,992 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $187,720 | 24,700 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $71,898 | 11,634 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $62,849 | 12,372 | Shares | Sole | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||